RecruitingPhase 2NCT06384378

Systemic and Central Inflammation in AD

Central and Peripheral Immune Cross-talk in Alzheimer's Disease and Their Modulation by a Novel Immunotherapy


Sponsor

The Methodist Hospital Research Institute

Enrollment

40 participants

Start Date

Mar 17, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Inflammation could provide a new focus for therapeutic intervention. In this study, we will measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to measurements of brain glial activation obtained by positron emission tomography (PET). In addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given over 22 weeks, on these inflammation biomarkers.


Eligibility

Min Age: 50 YearsMax Age: 86 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the role of inflammation — both in the body and in the brain — in Alzheimer's disease. Researchers will measure inflammatory markers in people with Alzheimer's to better understand how inflammation contributes to cognitive decline. **You may be eligible if...** - You are between 50 and 86 years old - You have been diagnosed with probable Alzheimer's disease - You have mild-to-moderate memory impairment (MMSE score 12–26) - You speak English and have at least 8 years of formal education - Your blood counts and organ function (liver, kidneys) are in acceptable range **You may NOT be eligible if...** - You have a serious active infection, severe heart or lung problems - You have a different type of dementia (e.g., Lewy body, frontotemporal) - You have had a stroke, brain tumor, or bleeding in the brain - You are allergic to IL-2 (the treatment used in this study) - You have active hepatitis B or C - You have been in another clinical trial in the past 30 days Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG11C-ER176

ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.


Locations(1)

Houston Methodist Research Institute

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06384378


Related Trials